CL2020001422A1 - Terapias con ligandos de proteína tipo lantionina c 2 y células preparadas con ellas - Google Patents
Terapias con ligandos de proteína tipo lantionina c 2 y células preparadas con ellasInfo
- Publication number
- CL2020001422A1 CL2020001422A1 CL2020001422A CL2020001422A CL2020001422A1 CL 2020001422 A1 CL2020001422 A1 CL 2020001422A1 CL 2020001422 A CL2020001422 A CL 2020001422A CL 2020001422 A CL2020001422 A CL 2020001422A CL 2020001422 A1 CL2020001422 A1 CL 2020001422A1
- Authority
- CL
- Chile
- Prior art keywords
- lanthionin
- therapies
- compounds
- cells
- cells prepared
- Prior art date
Links
- DWPCPZJAHOETAG-UHFFFAOYSA-N lanthionine Chemical compound OC(=O)C(N)CSCC(N)C(O)=O DWPCPZJAHOETAG-UHFFFAOYSA-N 0.000 title 1
- 239000003446 ligand Substances 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 title 1
- 238000002560 therapeutic procedure Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 210000004027 cell Anatomy 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000000094 Chronic Pain Diseases 0.000 abstract 1
- 208000035473 Communicable disease Diseases 0.000 abstract 1
- 208000001019 Inborn Errors Metabolism Diseases 0.000 abstract 1
- 102000008652 Lanthionine synthetase C-like Human genes 0.000 abstract 1
- 108050000440 Lanthionine synthetase C-like Proteins 0.000 abstract 1
- 208000002193 Pain Diseases 0.000 abstract 1
- 206010052779 Transplant rejections Diseases 0.000 abstract 1
- 230000001684 chronic effect Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000003463 hyperproliferative effect Effects 0.000 abstract 1
- 210000002865 immune cell Anatomy 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 208000016245 inborn errors of metabolism Diseases 0.000 abstract 1
- 208000027866 inflammatory disease Diseases 0.000 abstract 1
- 208000015978 inherited metabolic disease Diseases 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 230000037361 pathway Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0276—Knock-out vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4621—Cellular immunotherapy characterized by the effect or the function of the cells immunosuppressive or immunotolerising
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/46433—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0637—Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/075—Animals genetically altered by homologous recombination inducing loss of function, i.e. knock out
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/20—Animal model comprising regulated expression system
- A01K2217/206—Animal model comprising tissue-specific expression system, e.g. tissue specific expression of transgene, of Cre recombinase
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/15—Transforming growth factor beta (TGF-β)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2302—Interleukin-2 (IL-2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2312—Interleukin-12 (IL-12)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/30—Hormones
- C12N2501/38—Hormones with nuclear receptors
- C12N2501/385—Hormones with nuclear receptors of the family of the retinoic acid recptor, e.g. RAR, RXR; Peroxisome proliferator-activated receptor [PPAR]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Environmental Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biodiversity & Conservation Biology (AREA)
- Animal Husbandry (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Abstract
Se proporcionan compuestos que se dirigen a la ruta de la proteína 2 similar a la lantionina sintetasa C y a las células, como las células inmunes, preparadas in vitro con los compuestos. Los compuestos y las células se pueden usar para tratar una serie de afecciones, que incluyen enfermedades infecciosas, trastornos hiperproliferativos, errores innatos del metabolismo, enfermedades inmunometabólicas crónicas, enfermedades autoinmunes, rechazo de trasplantes de órganos, trastornos inflamatorios y dolor crónico, entre otros.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762592692P | 2017-11-30 | 2017-11-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2020001422A1 true CL2020001422A1 (es) | 2021-07-30 |
Family
ID=64664467
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2020001422A CL2020001422A1 (es) | 2017-11-30 | 2020-05-28 | Terapias con ligandos de proteína tipo lantionina c 2 y células preparadas con ellas |
Country Status (13)
Country | Link |
---|---|
US (2) | US11197891B2 (es) |
EP (1) | EP3717633A1 (es) |
JP (1) | JP2021503936A (es) |
KR (1) | KR20200090873A (es) |
CN (1) | CN111511904A (es) |
AU (1) | AU2018374767A1 (es) |
BR (1) | BR112020010983A2 (es) |
CA (1) | CA3083442A1 (es) |
CL (1) | CL2020001422A1 (es) |
EA (1) | EA202091325A1 (es) |
IL (1) | IL274989A (es) |
MX (1) | MX2020005525A (es) |
WO (1) | WO2019108418A1 (es) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113748109B (zh) | 2019-12-20 | 2023-07-21 | 朗多生物制药股份有限公司 | 羊毛硫氨酸c样蛋白2配体、用所述配体制备的细胞以及使用所述配体的疗法 |
WO2021174024A1 (en) | 2020-02-28 | 2021-09-02 | First Wave Bio, Inc. | Methods of treating iatrogenic autoimmune colitis |
WO2022057932A1 (zh) * | 2020-09-18 | 2022-03-24 | 上海医药集团股份有限公司 | 一种羰基杂环类化合物及其应用 |
US11459310B2 (en) | 2020-10-22 | 2022-10-04 | Landos Biopharma, Inc. | LANCL ligands |
WO2022098644A1 (en) | 2020-11-03 | 2022-05-12 | Landos Biopharma, Inc. | Crystalline forms of piperazine-1,4-diylbis((6-(1h-benzoi[d]imidazo-2-yl)pyridin-2yl)methanone) as lancl2 modulators |
EP4225315A2 (en) | 2020-11-19 | 2023-08-16 | Nimmune Biopharma, Inc. | Compounds, compositions, and methods for treating inflammatory or immune-mediated conditions of surface tissues |
WO2022127774A1 (zh) * | 2020-12-15 | 2022-06-23 | 成都百裕制药股份有限公司 | 吡啶衍生物及其在医药上的应用 |
Family Cites Families (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0282643A3 (en) | 1986-11-22 | 1990-08-22 | The Green Cross Corporation | Use of pharmaceutical compositions comprising cyclohexane derivatives in the treatment or prevention of peptic ulcers |
US5633388A (en) | 1996-03-29 | 1997-05-27 | Viropharma Incorporated | Compounds, compositions and methods for treatment of hepatitis C |
ATE288909T1 (de) | 1997-12-24 | 2005-02-15 | Nikem Research Srl | Indolderivate verwendbar zur behandlung von u.a. osteoporosis |
GB9914825D0 (en) | 1999-06-24 | 1999-08-25 | Smithkline Beecham Spa | Novel compounds |
GB0112834D0 (en) | 2001-05-25 | 2001-07-18 | Smithkline Beecham Plc | Medicaments |
TW200406413A (en) | 2002-06-26 | 2004-05-01 | Glaxo Group Ltd | Compounds |
JPWO2005037269A1 (ja) | 2003-10-21 | 2006-12-28 | 住友製薬株式会社 | 新規ピペリジン誘導体 |
JPWO2005082905A1 (ja) | 2004-02-26 | 2007-08-02 | 協和醗酵工業株式会社 | 二環性複素環化合物 |
US7674907B2 (en) | 2004-07-23 | 2010-03-09 | Amgen Inc. | Furanopyridine derivatives and methods of use |
EP1814393A4 (en) * | 2004-11-04 | 2010-02-03 | Med College Georgia Res Inst | TOLEROGENIC VACCINE AND METHOD THEREOF |
US7919487B2 (en) | 2004-11-10 | 2011-04-05 | Synta Pharmaceuticals Corporation | Heteroaryl compounds |
CA2596013C (en) | 2005-01-28 | 2012-06-05 | Daewoong Pharmaceutical Co., Ltd. | Benzoimidazole derivatives and pharmaceutical composition comprising the same |
GB0508314D0 (en) | 2005-04-25 | 2005-06-01 | Novartis Ag | Organic compounds |
CN100434419C (zh) | 2005-06-03 | 2008-11-19 | 中国人民解放军军事医学科学院毒物药物研究所 | 单环多取代饱和环已酮类化合物及其制备方法和用途 |
US7754724B2 (en) | 2005-06-30 | 2010-07-13 | Dow Agrosciences Llc | N-substituted piperazines |
CA2617532A1 (en) | 2005-08-04 | 2007-02-15 | Sirtris Pharmaceuticals, Inc. | Imidazo [2,1-b] thiazole derivatives as sirtuin modulating compounds |
UY29825A1 (es) | 2005-10-03 | 2007-05-31 | Astrazeneca Ab | Derivados sustituidos de 3h-imidazol-(4,5 b (beta))piridina-2-il benzoatos y benzamidas, composiciones farmacéuticas que los contienen y aplicaciones |
US20070203236A1 (en) | 2006-01-11 | 2007-08-30 | Smith Jeffrey W | Novel antagonists of the human fatty acid synthase thioesterase |
US8367727B2 (en) * | 2006-02-08 | 2013-02-05 | Virginia Tech Intellectual Properties, Inc. | Method of using abscisic acid to treat diseases and disorders |
US7741367B2 (en) | 2006-02-08 | 2010-06-22 | Virginia Tech Intellectual Properties, Inc. | Method of using abscisic acid to treat diseases and disorders |
JP2008056615A (ja) | 2006-08-31 | 2008-03-13 | Fujifilm Corp | ビニルエチニルアリールカルボン酸類、その製造方法及びそれを用いた熱架橋性化合物の製造方法 |
CA2670405A1 (en) | 2006-11-24 | 2008-05-29 | Waratah Pharmaceuticals Inc. | Combination treatments for alzheimer's disease and related neurodegenerative diseases |
JP2010513519A (ja) | 2006-12-22 | 2010-04-30 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | キナーゼインヒビター活性を有するある種のピラゾリン誘導体 |
MY146643A (en) | 2007-07-30 | 2012-09-14 | Dae Woong Pharma | Novel benzoimidazole derivatives and pharmaceutical composition comprising the same |
JP2011505341A (ja) | 2007-11-21 | 2011-02-24 | デコード ジェネティクス イーエイチエフ | 炎症性、心血管およびcns障害を治療するビアリールpde4抑制剤 |
EP2674417A3 (en) | 2007-11-21 | 2014-04-09 | Decode Genetics EHF | Biaryl PDE4 inhibitors for treating inflammation |
CA2647900C (en) | 2008-12-23 | 2017-05-16 | National Research Council Of Canada | Inhibitors of a 9-cis-epoxycarotenoid dioxygenase |
WO2010121046A1 (en) | 2009-04-17 | 2010-10-21 | Janssen Pharmaceutica Nv | 4-azetidinyl-1-phenyl-cyclohexane antagonists of ccr2 |
DE102009057167A1 (de) | 2009-12-05 | 2011-06-09 | Merck Patent Gmbh | Elektronische Vorrichtung enthaltend Metallkomplexe |
WO2011140215A2 (en) | 2010-05-04 | 2011-11-10 | Virginia Tech Intellectual Properties, Inc. | Lanthionine synthetase component c-like proteins as molecular targets for preventing and treating diseases and disorders |
US8993624B2 (en) | 2010-05-26 | 2015-03-31 | Virginia Tech Intellectual Properties, Inc. | Method of preventing and treating inflammatory diseases and disorders with abscisic acid |
TW201211027A (en) | 2010-06-09 | 2012-03-16 | Janssen Pharmaceutica Nv | Cyclohexyl-azetidinyl antagonists of CCR2 |
EP2582692B1 (en) | 2010-06-17 | 2015-07-22 | Janssen Pharmaceutica NV | Cyclohexyl-azetidinyl antagonists of ccr2 |
CA2861939A1 (en) | 2011-12-30 | 2013-07-04 | Centaurus Biopharma Co., Ltd. | Novel arylalkene derivatives and use thereof as selective estrogen receptor modulators |
RS61013B1 (sr) | 2014-10-24 | 2020-11-30 | Landos Biopharma Inc | Terapeutski preparati zasnovani na lantionin sintetazi c- sličnom proteinu-2 |
-
2018
- 2018-11-16 EP EP18816385.1A patent/EP3717633A1/en not_active Withdrawn
- 2018-11-16 KR KR1020207018225A patent/KR20200090873A/ko unknown
- 2018-11-16 CA CA3083442A patent/CA3083442A1/en active Pending
- 2018-11-16 MX MX2020005525A patent/MX2020005525A/es unknown
- 2018-11-16 WO PCT/US2018/061588 patent/WO2019108418A1/en active Application Filing
- 2018-11-16 BR BR112020010983-5A patent/BR112020010983A2/pt not_active IP Right Cessation
- 2018-11-16 US US16/193,640 patent/US11197891B2/en active Active
- 2018-11-16 CN CN201880083726.2A patent/CN111511904A/zh active Pending
- 2018-11-16 EA EA202091325A patent/EA202091325A1/ru unknown
- 2018-11-16 AU AU2018374767A patent/AU2018374767A1/en not_active Abandoned
- 2018-11-16 JP JP2020529583A patent/JP2021503936A/ja active Pending
-
2020
- 2020-05-28 CL CL2020001422A patent/CL2020001422A1/es unknown
- 2020-05-28 IL IL274989A patent/IL274989A/en unknown
-
2021
- 2021-11-12 US US17/524,883 patent/US20220072044A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
MX2020005525A (es) | 2020-10-28 |
US20220072044A1 (en) | 2022-03-10 |
CA3083442A1 (en) | 2019-06-06 |
CN111511904A (zh) | 2020-08-07 |
US11197891B2 (en) | 2021-12-14 |
AU2018374767A1 (en) | 2020-06-25 |
EA202091325A1 (ru) | 2020-08-28 |
KR20200090873A (ko) | 2020-07-29 |
WO2019108418A1 (en) | 2019-06-06 |
US20190160100A1 (en) | 2019-05-30 |
EP3717633A1 (en) | 2020-10-07 |
BR112020010983A2 (pt) | 2020-11-17 |
IL274989A (en) | 2020-07-30 |
JP2021503936A (ja) | 2021-02-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2020001422A1 (es) | Terapias con ligandos de proteína tipo lantionina c 2 y células preparadas con ellas | |
CY1123142T1 (el) | Βελτιωμενες μεθοδοι για την παραγωγη θετων κυτταρικων θεραπειων | |
CU20110096A7 (es) | Compuestos que expanden las células madre hematopoyéticas | |
DOP2016000238A (es) | Sistema y método de mercadeo dirigido de selección previa digital | |
SV2017005367A (es) | Composiciones y métodos de uso para tratar trastornos metabólicos | |
MA38860B1 (fr) | Cellule progénitrice immuno-modulatrice (imp) | |
EA201592103A2 (ru) | Способы и композиции для усиления cd4+ регуляторных t-клеток | |
BR112016023523A2 (pt) | produtos de células t modificados em gene de composição definida | |
PH12021551189A1 (en) | Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo | |
JP2014141525A5 (es) | ||
AR092188A1 (es) | ANTICUERPOS HUMANOS PARA GFRa3 Y METODOS PARA SU USO | |
BR112016029558A2 (pt) | terapia de células-tronco em patologias endometriais | |
MX2020005849A (es) | Células madre y progenitoras hematopoyéticas humanas cd34+ modificadas con crispr-cas9 y sus usos. | |
EA201791416A1 (ru) | Популяции клеток rpe и способы их получения | |
MA52542A (fr) | Thérapie cellulaire adoptive | |
MX2021003797A (es) | Terapias inmunoablativas. | |
CO2019009080A2 (es) | Péptidos y métodos para el tratamiento de diabetes | |
BR112019022901A2 (pt) | precursor de linhagem mesenquimal ou células t com imunossupressão intensificada | |
AR108134A1 (es) | Diferenciación de células madre pluripotentes en células del endodermo del intestino medio | |
BR112023005376A2 (pt) | Composições de oligossacarídeos e métodos de uso | |
EA201890439A1 (ru) | ИММУНООНКОЛОГИЧЕСКАЯ МЕЗОДЕРМАЛЬНАЯ КЛЕТКА-ПРЕДШЕСТВЕННИК (ioMP-КЛЕТКА) | |
EA201790615A1 (ru) | Композиции и способы увеличения захвата железа у млекопитающих | |
IN2014DN08964A (es) | ||
ZA202103634B (en) | Use of an egg grafted with tumor cells in order to study the anti-cancer effectiveness of immune therapies in the absence of immune effector cells other than those in the grafted egg | |
MX2021002045A (es) | Composiciones y métodos para la producción de biofármacos libres de antibióticos en cloroplastos de lechuga. |